Profile: OncoGenex Pharmaceuticals Inc (OGXI.OQ)
26 May 2015
OncoGenex Pharmaceuticals, Inc. (OncoGenex), incorporated on March 22, 1995, is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The Company has three product candidates in its pipeline: custirsen, apatorsen and OGX-225. The Company’s product candidate’s custirsen, apatorsen and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumour cells and are over-produced in response to a variety of cancer treatments. Custirsen blocks the production of the protein clusterin, which plays a fundamental role in cancer cell survival and treatment resistance. Apatorsen is a once-weekly intravenous (IV) experimental drug inhibits production of Hsp27 to disable cancer cells’ defenses and overcome treatment resistance. OGX-225 inhibits the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that when overexpressed affect the growth of cancer cells.
The Company have developed a clinical development plan under which three Phase III clinical trials have been initiated such as, The SYNERGY Trial, The AFFINITY Trial and The ENSPIRIT Trial. The SYNERGY, Phase III clinical trial evaluates survival benefit for custirsen in combination with first-line docetaxel treatment in patients with castrate resistant prostate cancer, or CRPC. The AFFINITY , Phase III clinical trial evaluates a survival benefit for custirsen in combination with cabazitaxel treatment as second-line chemotherapy in patients with CRPC. The ENSPIRIT, Phase III clinical trial evaluates a survival benefit for custirsen in combination with docetaxel treatment as second-line chemotherapy in patients with non-small cell lung cancer, or NSCLC. Custirsen has received fast track designation from the U.S. Food and Drug Administration, or FDA, for second-line treatment of metastatic CRPC when combined with cabazitaxel and prednisone and for the second-line treatment of advanced NSCLC when combined with docetaxel in patients with disease progression following treatment with a first-line, platinum-based chemotherapy doublet regimen.
The Company’s product Apatorsen inhibit production of heat shock protein 27, or Hsp27, a cell-survival protein expressed in many types of cancers including bladder, non-small cell lung, pancreatic, prostate and breast cancers. It is in Phase II clinical trials. Hsp27 expression is stress-induced, including by many anti-cancer therapies. Overexpression of Hsp27 is an important factor leading to the development of treatment resistance and is associated with metastasis and negative clinical outcomes in patients with various tumour types. In 2013, it initiated the ORCA (On-going studies evaluating treatment Resistance in CAncer) program which encompasses clinical studies evaluates whether inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients. The Company conducts parallel clinical trials to evaluate apatorsen in several cancer indications and treatment combinations to accelerate the development of apatorsen. Apatorsen development activities include the clinical trials such as, Borealis-1trial and Borealis-2 trial for bladder cancer; The Spruce Trial and The Cedar Trial for treatment of non-small cell lung cancer (NSCLC), The Rainier Trial for the treatment of pancreatic cancer, and The Pacific Trial for the treatment of prostate cancer.
The Company’s product candidate OGX-225 is in pre-clinical development and it inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that when overexpressed affect the growth of cancer cells. Increased IGFBP-2 and IGFBP-5 production are observed in many human cancers, including prostate, breast, colorectal, non-small cell lung, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, and melanoma. The increased production of these proteins is linked to faster rates of cancer progression, treatment resistance, and shorter survival duration in humans. Preclinical studies with human prostate and breast cancer cells have shown that reducing IGFBP-2 and IGFBP-5 production with OGX-225 sensitized these tumour types to hormone ablation therapy or chemotherapy and induced tumour cell death.
OncoGenex Pharmaceuticals Inc
19820 N Creek Pkwy Ste 201
BOTHELL WA 98011-8227